Sign In
Buy RGEN
$149.78
+2.72 (+1.85%)
At Close: Aug 04, 2026
Repligen Corporation $RGEN Shares Acquired by Avidity Partners Management LP
03:50am, Saturday, 01'st Aug 2026
Avidity Partners Management LP increased its position in shares of Repligen Corporation (NASDAQ: RGEN) by 54.7% in the undefined quarter, according to the company in its most recent Form 13F filing wi
Wall Street Analysts Believe Repligen (RGEN) Could Rally 25.72%: Here's is How to Trade
10:56am, Thursday, 30'th Jul 2026
The consensus price target hints at a 25.7% upside potential for Repligen (RGEN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
Repligen Beats Q2 Earnings Estimates, Raises 2026 View, Stock Up
01:26pm, Wednesday, 29'th Jul 2026
RGEN tops Q2 earnings and revenue estimates, lifts its 2026 revenue and EPS outlook, and sees shares jump after stronger-than-expected results.
Repligen Corporation (RGEN) Q2 2026 Earnings Call Transcript
01:23pm, Tuesday, 28'th Jul 2026
Repligen Corporation (RGEN) Q2 2026 Earnings Call Transcript
Repligen Q2 Earnings Call Highlights
11:05am, Tuesday, 28'th Jul 2026
Repligen NASDAQ: RGEN reported second-quarter 2026 revenue of $204 million, up 12% year over year on a reported basis and 13% organically, as demand for proteins, analytics products and recurring cons
Repligen (RGEN) Beats Q2 Earnings and Revenue Estimates
09:16am, Tuesday, 28'th Jul 2026
Repligen (RGEN) came out with quarterly earnings of $0.54 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.37 per share a year ago.
Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
07:00am, Tuesday, 28'th Jul 2026
WALTHAM, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its s
American Capital Management Inc. Purchases 22,605 Shares of Repligen Corporation $RGEN
03:50am, Tuesday, 28'th Jul 2026
American Capital Management Inc. increased its position in shares of Repligen Corporation (NASDAQ: RGEN) by 6.7% in the first quarter, according to the company in its most recent filing with the Secur
Repligen Corporation $RGEN Shares Purchased by First Trust Advisors LP
04:23am, Sunday, 26'th Jul 2026
First Trust Advisors LP raised its position in Repligen Corporation (NASDAQ: RGEN) by 122.8% during the first quarter, according to the company in its most recent disclosure with the Securities and Ex
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale
Repligen to Expand Cell Therapy Capabilities With BioLife Buyout
12:41pm, Thursday, 23'rd Jul 2026
RGEN's $1.5 billion BioLife acquisition aims to expand its cell therapy capabilities, adding biopreservation products and expected revenue and EPS benefits.
Repligen Corporation (RGEN) M&A Call Transcript
05:10am, Thursday, 23'rd Jul 2026
Repligen Corporation (RGEN) M&A Call Transcript
Repligen to Buy BioLife Solutions for $1.5 Billion, Expanding Cell Therapy Reach
03:04pm, Wednesday, 22'nd Jul 2026
Repligen NASDAQ: RGEN said it has signed a definitive agreement to acquire BioLife Solutions in a transaction valued at approximately $1.5 billion, adding a cell therapy-focused platform that manageme
Repligen Strengthens Cell Therapy Portfolio With BioLife Acquisition
09:41am, Wednesday, 22'nd Jul 2026
Life sciences company Repligen Corporation (NASDAQ:RGEN) on Wednesday agreed to acquire cell processing developer BioLife Solutions Inc. (NASDAQ:BLFS) for an enterprise value of approximately $1.5 bil
Repligen to buy cell therapy maker BioLife in $1.5 billion deal
06:13am, Wednesday, 22'nd Jul 2026
Repligen Corp said on Wednesday it would buy BioLife Solutions in a cash-and-stock deal valued at about $1.5 billion, to expand the drugmaking equipment provider's presence in the fast-
